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Abstract
Background Obesity is a risk factor for glucose intolerance, but the independent
role of obesity in the development of peripheral neuropathy is unclear. This study
assessed the impact of body size trajectories on prevalent nerve dysfunction in
community-dwelling women with and without glucose intolerance.
Methods Annual (1996–2008) anthropometric measures of weight, height,
waist circumference and body mass index [BMI, weight (kg)/height (m2)]
were assessed in the Study of Women’s Health Across the Nation – Michigan
site. Glucose intolerance was defined annually on the basis of current use of
diabetes medications, self-reported diabetes diagnosis and, when available,
fasting glucose. Peripheral nerve dysfunction in 2008 was defined as abnormal
monofilament testing or ≥4 symptoms or signs. Linear mixed models were
used to determine trajectories of anthropometry by subsequently identified
nerve dysfunction status.
Results Mean BMI was 32.4 kg/m2 at baseline, and 27.8% of the women had
nerve dysfunction in 2008. BMI, weight and waist circumference increased over
time. Women who would have nerve dysfunction were significantly larger than
women without dysfunction, independent of glucose intolerance. At mean
baseline age of 46, BMI, weight and waist circumference differed significantly
(p-value< 0.01) by subsequent nerve dysfunction status, independent of glucose
intolerance and hypertension. These body size differences were maintained but
not exacerbated over time.
Conclusions Peripheral nerve dysfunction is prevalent among community-
dwelling women. Twelve years before the nerve assessment, anthropometry
differed between women who would and would not have nerve dysfunction,
differences that were maintained over time. Obesity deserves attention as an
important and potentially modifiable risk factor for peripheral nerve dysfunction.
Copyright © 2012 John Wiley & Sons, Ltd.
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Introduction
Currently, two thirds of adults in the United States are overweight or obese [1].
The high prevalence of obesity is a major public health problem because obesity
is associated with a variety of chronic diseases, decreased quality of life and
premature death [2,3]. In particular, obesity is a well-documented risk factor
for impaired fasting glucose (IFG) and diabetes mellitus [4,5]. Peripheral nerve
dysfunction is a common complication of diabetes mellitus, but the role of obesity
in the development of peripheral nerve dysfunction, independent of glucose
intolerance, is not well understood [6–8].
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The pathogenesis of peripheral nerve dysfunction has
gained recent attention as an important focus of scientific
study [9]. Although diabetic peripheral neuropathy is the
most common type of neuropathy, it is estimated that
among individuals with diabetes, up to 50% may have an
additional cause of generalized neuropathy [9]. Further-
more, many individuals with diabetes have neuropathy at
the time of their diagnosis [10], suggesting that neuropathy
may be associated with IFG and may precede, rather than
follow, overt type 2 diabetes [11–13]. In addition, the devel-
opment of peripheral neuropathy in diabetic patients with
tight glycemic control suggests a role for risk factors inde-
pendent of chronic hyperglycemia [14].
Obesity may be an important catalyst in a cascade of
factors leading to peripheral nerve damage. Obesity may
increase the risk of peripheral nerve dysfunction through
IFG [15,16], damaging small nerve fibres as the earliest
detectable sign of peripheral neuropathy in glucose deregu-
lation [11,17]. Alternatively, microvascular damage from
subclinical cardiovascular abnormalities may also contrib-
ute to nerve dysfunction [11]. Recent evidence suggests
that ageing, oxidative stress and dyslipidemia, independent
of diabetes, may be plausible causal mechanisms [18–20].
Furthermore, obesity may be an important consequence of
peripheral nerve dysfunction if individuals with sensory
deficits or pain in the lower extremities experience declin-
ing levels of physical functioning.
Peripheral nerve dysfunction is an under-appreciated
condition that has adverse effects on mobility, physical
functioning and quality of life [21]. Assessing the potential
role for obesity or body size in the development of periph-
eral nerve dysfunction is important because obesity can be
prevented ormanaged through education, diet and physical
activity. We evaluated trajectories of anthropometric mea-
sures and prevalent peripheral nerve dysfunction in a popu-
lation-based cohort of African American and Caucasian
mid-life women with and without glucose intolerance in
the United States. We hypothesized that women who had
nerve dysfunction would be more obese and have greater
changes in their body size over time than women without
nerve dysfunction, independent of glucose intolerance.
Materials and methods
Study population
The Study of Women’s Health Across the Nation (SWAN)
is an ongoing population-based longitudinal study of
women from seven sites in the United States [22]. This
investigation focused on the Michigan SWAN cohort of
543 women (325 African American and 218 Caucasian)
selected from two communities near Detroit who in
1996 were aged 42–52 years, had an intact uterus and
at least one ovary, reported no current use of hormones
and had at least one menstrual period in the prior
3 months. Of the original sample, 418 (77%) were still
active in study year 12 (2008) and eligible to participate
in the peripheral neuropathy sub-study. Of these, 396
(95%) underwent a foot examination and/or completed a
symptom questionnaire for peripheral nerve dysfunction.
Women who participated in the neuropathy sub-study did
not differ by race/ethnicity or baseline age, weight, height,
waist and hip circumference, blood pressure and fasting
glucose from women who did not participate. The parent
and sub-study were approved by the University of Michigan
Health Institutional Review Board, and all participants
provided written informed consent.
Study variables
Peripheral nerve dysfunctionwas assessed using theMichigan
Neuropathy Screening Instrument (MNSI) symptom ques-
tionnaire [23] and monofilament testing [24] in year 12
(2008) of the study. The MNSI symptom questionnaire is
a 15-item questionnaire used to acquire information about
the presence (yes/no) of common neuropathy symptoms
and signs, including numbness, pain, sensitivity, cramping,
prickling feelings, hot/cold differentiation, open sores,
dryness, weakness and amputation. Monofilament testing
used the placement of a 10-g pre-stressed filament on the
dorsal side of the big toe, midway between the nail fold
and the distal interphalangeal joint briefly (<1 s) for ten
repetitions. The participant was asked to respond if she felt
the filament following each repetition. Peripheral nerve
dysfunction was defined as 80% or fewer correct responses
to the brief sensation in either foot [25] or≥4 symptoms or
signs reported on the MNSI questionnaire [26].
A total of 110 women was classified as having peripheral
nerve dysfunction: 33 women had abnormal monofilament
testing, 57 women reported ≥4 signs or symptoms and
20 women had both. In a preliminary analysis, these two
methods identified similar womenwith respect to body size
measurements, so women classified with dysfunction by
either method were combined for subsequent analyses.
The use of two different instruments to assess the presence
of peripheral nerve dysfunction may capture different types
and/or sizes of damaged nerves [27].
Age in years was calculated from the interval of birth to
follow-up visit date. Race/ethnicity was self-identified at
the 1996 baseline as African American or Caucasian.
Annual (baseline through year 12) anthropometric
measures were collected from each participant. Height
was measured without shoes in centimetres by fixed
stadiometer. Weight was measured in light clothing in
kilogrammes by balance beam scale. Body mass index
(BMI) was calculated as weight (kg)/height (m2). Waist
and hip circumferences were measured in centimetres by
a non-stretching tape measure. BMI, weight and waist
circumference were identified a priori as the primary
obesity measures of interest for our investigation. BMI
≥30 kg/m2 and waist circumference ≥88 cm were used as
risk cut points to identify anthropometric obesity.
Blood pressure (mmHg) was measured according to
a standard protocol using a mercury sphygmomanometer
following an initial minimum 5 min resting period.
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Participants were classified as hypertensive if their average
systolic blood pressure was ≥140 mmHg, average diastolic
blood pressure was ≥90 mmHg or if they reported current
use of hypertension treatment.
Fasting blood samples were collected from participants,
and fasting glucose was assessed at baseline and in study
visit (V) 1, V3, V4, V5, V6, V7 and V12. For this sub-study,
samples were assayed for blood glucose (mg/dL) at the
Michigan Diabetes Research and Training Center in
Ann Arbor, MI, USA. In V12 (2008), the inter-assay coeffi-
cient of variation was 3.6% at 92 mg/dL and 2.8% at
310 mg/dL; the intra-assay coefficient of variation was
2.0% at 84 and 283 mg/dL. For each study visit, diabetes
mellitus status was defined using fasting glucose
≥126 mg/dL when available and/or affirmative responses
to annual questions about diagnosed diabetes or current
use of antidiabetic medications. Women without diabetes
were further classified as having IFG (100–125 mg/dL) or
normal fasting glucose (<100 mg/dL). In addition, a
three-level cumulative longitudinal status variable was
created for ever-diabetes, ever-IFG but never diabetes and
always-normal fasting glucose during the study period.
Statistical analysis
First, means standard deviation (SD) and frequencies
were calculated to quantify baseline study population
characteristics. We evaluated the overall prevalence of
peripheral nerve dysfunction and the prevalence by catego-
ries of cumulative glucose tolerance status. Chi-square tests
or student’s t-tests were used to compare baseline popula-
tion characteristics between women with and without
prevalent peripheral nerve dysfunction in study year 12.
Next, multivariable logistic regression was used to deter-
mine the association between anthropometric measures
and peripheral nerve dysfunction in year 12. Model 1 eval-
uated the association between baseline BMI and nerve
dysfunction, adjusted for baseline age, race/ethnicity, base-
line hypertension and baseline glucose tolerance status.
Model 2 substituted baseline weight for BMI, and Model
3 substituted baseline waist circumference. Models 2 and
3 also added height as a covariate because of its association
with neuropathy [28].
Third, we evaluated how BMI (kg/m2 SD), weight
(kg SD) andwaist circumference (cm SD) changed from
baseline to year 12. Student’s t-tests were used to compare
baseline and year 12 anthropometric measures between
women with and without nerve dysfunction in year 12.
Fourth, we compared the prevalence of nerve dysfunc-
tion and other characteristics in year 12 between women
who were and were not obese in year 12 according to
BMI and waist circumference risk cut points. Chi-square
tests and student’s t-tests were used to generate p-values.
Finally, linear mixed models (PROC MIXED) with random
intercepts and slopes for age were used to measure trajecto-
ries of anthropometry over time by subsequent peripheral
nerve dysfunction status. BMI, weight and waist circumfer-
ence were log-transformed to meet model assumptions of
homoscedasticity and then back-transformed to the
geometric mean of their original scale for graphical and
numerical presentation. The BMI model was adjusted for
cumulative glucose tolerance status and hypertension, and
the weight and waist models were adjusted for cumulative
glucose tolerance status, hypertension and height. SAS
(version 9.3) was used for all data management and analy-
sis. Statistical tests were two-sided with the level of signifi-
cance defined as p-value <0.05.
Results
Average age at baseline was 46.2 years. The study popula-
tion was 40% Caucasian and 60% African American, by
design. At baseline, mean BMI was 32.4 kg/m2, mean
weight was 86.4 kg, mean waist circumference was
94.4 cm, 8.3% of the participants had diabetes, 24.0%
had IFG and 26.5% were hypertensive.
Overall, 27.8% of the women had peripheral nerve
dysfunction in study year 12. The prevalence of nerve
dysfunction increased across categories of cumulative
glucose tolerance status: 21.3% of the women with normal
glucose tolerance had nerve dysfunction, 26.4% of the
women with ever-IFG had nerve dysfunction and 36.6% of
the women with ever-diabetes had nerve dysfunction.
At baseline, women who would have peripheral nerve
dysfunction in study year 12 already had significantly larger
body sizes than womenwhowould not have neuropathy. In
addition, women with nerve dysfunction in study year 12
were more likely to have glucose intolerance at baseline
compared with womenwho did not have nerve dysfunction
in study year 12 (Table 1).
In multivariable models adjusted for age, race/ethnicity,
hypertension and glucose intolerance, baseline BMI
(p-value= 0.01) was a significant predictor of having
peripheral nerve dysfunction 12 years later. Baseline
weight (p-value= 0.002) and waist circumference
(p-value= 0.0004), independent of height, were also
significant predictors of peripheral nerve dysfunction
in study year 12 (Table 2).
In the total study population, increases in average BMI,
weight and waist circumference were observed during the
course of the study. Between baseline and study year 12,
average BMI increased from 32.4 to 34.0 kg/m2, average
weight increased from 86.4 to 89.9 kg and average waist
circumference increased from 94.5 to 101.3 cm. Baseline
and year 12 body size measurements differed significantly
between women with and without peripheral nerve
dysfunction in study year 12.
In study year 12, 63.0% of the study population had a
BMI ≥30 kg/m2, and these women were more likely to
have peripheral nerve dysfunction, a waist circumference
≥88 cm, hypertension and glucose intolerance. In study
year 12, 75.6% of the study population had a waist
circumference ≥88 cm, and these women were more
likely to have a BMI ≥30 kg/m2, hypertension and
glucose intolerance. They were also more likely to have
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peripheral nerve dysfunction, but the difference was not
statistically significant.
In the mixed model analysis at the mean baseline age of
46 years, we observed significantly higher BMI (p-value=
0.003), waist circumference (p-value=0.001) and weight
(p-value=0.001) inwomenwith peripheral nerve dysfunc-
tion in study year 12, independent of cumulative glucose
intolerance status and hypertension. However, although
mean obesity changed over time, body size differences
between women who would and would not have nerve
dysfunction were maintained over time, and we observed
no differences in annual percent increase in obesity by
peripheral nerve dysfunction status. On average, BMI
increased by 0.34% (95% confidence interval (CI): 0.14,
0.54) per year for women who had nerve dysfunction in
year 12 and by 0.35% (95% CI: 0.23, 0.48) for women
who did not have nerve dysfunction in year 12. On average,
waist circumference increased by 0.61% (95% CI: 0.45,
0.76) per year for women who had nerve dysfunction in
year 12 and by 0.60% (95% CI: 0.50, 0.69) for women
who did not have nerve dysfunction in year 12. On average,
weight increased by 0.29% (95% CI: 0.09, 0.49) per year
for women who had nerve dysfunction in year 12 and by
0.32% (95% CI: 0.20, 0.45) for women who did not have
nerve dysfunction in year 12. The trajectories of body sizes
over time by peripheral nerve dysfunction status in year
12 are depicted in Figure 1(A–C).
Discussion
To our knowledge, this is the first investigation of the
prevalence of peripheral nerve dysfunction and trajecto-
ries of body size in a population-based cohort of commu-
nity-dwelling women. We found significant differences in
BMI, waist circumference and weight between women
with peripheral nerve dysfunction and women without
peripheral nerve dysfunction 12 years before the assess-
ment of peripheral nerve dysfunction, differences that
persisted over time. Notably, these differences were
present independent of glucose intolerance, suggesting a
possible independent role for obesity or obesity-related
factors in the aetiology of nerve dysfunction. Trajectories
Table 1. Baseline (1996) characteristics of women by peripheral nerve dysfunction status in 2008, Michigan SWAN
Total (n=396) PND (n=110) No PND (n=286) p-value
Age, years (SD) 46.2 (2.7) 46.3 (2.6) 46.1 (2.8) 0.39
Race/ethnicity, %
Caucasian 40.4 40.9 40.2 0.90
African American 59.6 59.1 59.8
Weight, kg (SD) 86.4 (21.9) 94.2 (23.8) 83.4 (20.4) <0.0001
Height, cm (SD) 163.4 (6.1) 164.4 (6.1) 163.0 (6.1) 0.04
Body mass index, kg/m2 (SD) 32.4 (8.1) 34.9 (8.5) 31.4 (7.7) 0.0002
Waist, cm (SD) 94.4 (17.3) 100.9 (19.3) 92.0 (15.8) <0.0001
Hip, cm (SD) 114.3 (16.2) 119.5 (18.5) 112.3 (14.8) 0.0003
Waist-to-hip ratio 0.82 (0.07) 0.84 (0.08) 0.82 (0.07) 0.005
Hypertension, % 26.5 30.9 24.8 0.22
Diabetes status, %
Normal 67.4 55.5 72.0 0.003
Impaired fasting glucose 24.0 30.0 21.7
Diabetes 8.6 14.6 6.3
SWAN, Study of Women’s Health Across the Nation; PND, peripheral nerve dysfunction; SD, standard deviation.
Table 2. Multivariable associations (odds ratio (95% CI)) between baseline measures and peripheral nerve dysfunction in year 12,
Michigan SWAN
Model 1 Model 2 Model 3
Baseline measures OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Age, years 1.04 (0.96, 1.13) 0.36 1.06 (0.97, 1.15) 0.21 1.05 (0.96, 1.14) 0.27
Race/ethnicity
Caucasian (reference) 1.00 1.00 1.00
African American 0.98 (0.61, 1.57) 0.93 0.93 (0.57, 1.51) 0.77 0.96 (0.59, 1.56) 0.86
BMI, kg/m2 (per 5 units) 1.24 (1.06, 1.44) 0.01 — —
Weight, kg (per 5 units) — 1.09 (1.03, 1.16) 0.002 —
Height, cm — 1.04 (1.00, 1.08) 0.09 1.04 (1.00, 1.08) 0.03
Waist circumference, cm (per 5 units) — — 1.14 (1.06, 1.22) 0.0004
Hypertension (yes vs no) 1.01 (0.59, 1.72) 0.96 1.07 (0.62, 1.83) 0.81 1.02 (0.60, 1.76) 0.94
Diabetes status
Normal (reference) 1.00 1.00 1.00
Impaired fasting glucose 1.45 (0.84, 2.50) 0.18 1.37 (0.79, 2.38) 0.20 1.27 (0.73, 2.20) 0.41
Diabetes 2.09 (0.96, 4.58) 0.07 2.22 (1.00, 4.90) 0.05 2.03 (0.92, 4.48) 0.09
SWAN, Study of Women’s Health Across the Nation; BMI, body mass index; OR, odds ratio; CI, confidence interval.
Model 1 uses baseline BMI as the body size measure, Model 2 substitutes baseline weight and height for BMI and Model 3 substitutes
baseline waist circumference and height for BMI.
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of body size measurements were approximately parallel,
suggesting that women who would have peripheral nerve
dysfunction did not get obese at a faster rate than women
without nerve dysfunction.
Our findings that anthropometric measurements are
associated with peripheral nerve dysfunction are consis-
tent with other studies. Among individuals with diabetes,
BMI has been demonstrated to be a significant predictor
of incident neuropathy, independent of diabetes duration
and glucose control [14,29]. Two cross-sectional analyses
from the National Health and Nutrition Examination
Survey found a significant association between anthro-
pometry and peripheral neuropathy measured with
monofilament testing. One study reported that weight
was significantly associated with neuropathy in persons
without diabetes, independent of height, age and glycated
haemoglobin A1c [28]. Another study reported that
obesity (BMI≥ 30 kg/m2) and the clustering of abnormal
cardiovascular risk factors were positively associated with
neuropathy in US adults [30].
The mechanism by which obesity confers a greater risk
of peripheral neuropathy is not entirely clear. Adiposity is
associated with age, increased oxidative stress, pro-
inflammatory cytokines and dyslipidemia [31–33], which
may damage peripheral nerves even in the absence of
hyperglycemia [18–20]. Future research should assess the
role of specific metabolic products of adipose tissue with
respect to neuropathy aetiology because anthropometric
measures may be an incomplete proxy of the metabolic
environment of obesity [15], particularly considering the
proportion ofmetabolically unhealthy but non-obese indivi-
duals in the United States [34].
Nevertheless, BMI, waist circumference and weight are
important indicators of an individual’s metabolic environ-
ment. We found that women who were obese according to
anthropometric risk cut points were also more likely to
have hypertension and glucose intolerance. BMI and waist
circumference in particular correlatewell to body composition
values, and the use of waist circumference over waist-to-hip
ratio is gaining support as a simpler alternative to identify
adiposity [15,35,36]. BMI and waist circumference are also
highly correlated with abnormal metabolic values, over and
above measures of percent body fat mass [37]. Although we
did not have complete longitudinal measures of triglycerides
and cholesterol in this population over time, women with
peripheral nerve dysfunction were more likely to report use
of lipid-lowering agents (32.7% vs 21.7%; p-value=0.02)
2 years prior to our assessment of nerve dysfunction, lending
possible support for a dyslipidemia mechanism.
Our measurement of peripheral nerve dysfunction was
conducted 12 years after cohort enrollment. We hypothe-
sized that obesity would both cause nerve dysfunction
and increase as a result of nerve dysfunction. However,
we found no difference in the trajectories (i.e. slopes) of
body size measures by nerve dysfunction status. Either
peripheral nerve dysfunction developed late during the
course of the study and did not have a chance to change
the trajectory of obesity or obesity caused nerve dysfunc-
tion but did not change as a result of neuropathy. Given
the low likelihood that many of the study participants
had nerve dysfunction at baseline and the parallel anthro-
pometric trajectories of women with and without nerve




Figure 1. Predicted trajectories of body mass index (A), waist
circumference (B) and weight (C) by peripheral nerve dysfunction
status in 2008, adjusted for cumulative glucose tolerance status
and hypertension (A) or cumulative glucose tolerance status,
hypertension and height (B and C), Michigan Study of Women’s
Health Across the Nation. Large dashed lines are trajectories for
peripheral nerve dysfunction, solid lines are trajectories for
women without peripheral nerve dysfunction and small dashes
are 95% confidence intervals
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caused obesity in this population. However, future studies
should establish the timing and causal relationship between
obesity and peripheral nerve dysfunction. Furthermore,
two thirds of our study population was obese. Future stud-
ies may wish to evaluate which correlates of obesity are
most strongly associated with nerve dysfunction so that
targeted interventions can be developed, particularly in
more heterogeneous populations with respect to body size.
Neuropathy has many possible causes [18]. Our assess-
ment of nerve dysfunction was limited to simple, non-
invasive measures appropriate for an observational cohort
and did not represent a definitive diagnosis of peripheral
neuropathy. We were unable to distinguish between the
different mechanisms by which obesity may cause nerve
dysfunction or eliminate all other causes of peripheral nerve
dysfunction. Age-related declines in peripheral nerve func-
tion are well documented [20,38,39]. Additional causes of
neuropathy include exposure to toxins, vitamin B12 defi-
ciency and alcohol abuse. We would expect toxin exposure
to occur randomly, independent of obesity, andwould there-
fore not confound the association between obesity and nerve
dysfunction. Although we cannot rule out vitamin B12
malabsorption, no statistically significant differences in
vitamin B12 dietary and supplement intake by nerve
dysfunction were observed 3 years prior to the assessment
of nerve dysfunction, and less than 5% of our participants
reported excessive alcohol consumption (i.e.≥1 drink/day).
Peripheral neuropathy symptoms, including pain, may in-
terfere with mobility and quality of life [20,40]. In a small
study of subjects with impaired glucose tolerance and neu-
ropathy, diet and exercise education to improve impaired
glucose tolerance also lowered BMI and neuropathic pain
[41]. Clearly, neuropathy treatment should target the under-
lying cause to prevent or slow the progression of the disease
[42,43]. BMI, waist circumference and weight are easy to
measure and readily available to the patient and clinician
alike. Identifying easy-to-measure and modifiable risk
factors for chronic diseases is an important epidemiologic
endeavour, particularly as our population ages. Clinicians
who attend obese patients may wish to employ peripheral
nerve dysfunction testing because anthropometric measures
and their correlates may prove to be important targets for
interventions to prevent neuropathy or improve pain.
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